Products
Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-740
Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Asfotase alfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia.[3][4][5][6]
Asfotase alfa is an enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). Hypophosphatasia is caused by a genetic defect of tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme that plays a role in bone mineralization. Asfotase alfa is a recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP. It is therefore used as an enzyme replacement therapy
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-740-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-740-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-740-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-740-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) |
| INN Name | Asfotase Alfa |
| Target | Enzyme |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18- 502]2 - IGHG1 Fc (Fragment constant) - Asp-Ile- deca-aspartate |
| VD LC | Fusion - [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18- 502]2 - IGHG1 Fc (Fragment constant) - Asp-Ile- deca-aspartate |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Alexion Pharmaceuticals Inc. (New Haven CT USA) / Enobia pharma (Cambridge MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
